CSRHub is the world’s largest CSR (corporate social responsibility) and sustainability ratings and information database.

Researches, develops, produces and markets medicines for serious health conditions

Ticker: AZN-LN ISIN: GB0009895292
Address: 1800 Concord Pike , United Kingdom , Wilmington , , DE 19850-5437 Website: AstraZeneca
Phone #: 1-302-886-3000 CSR Web Area: SUBSCRIPTION INFO

Basic Corporate Social Responsibility (CSR) Ratings

  Overall Community Employees Environment Governance
AstraZeneca 66 66 65 69 64
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 55 55 56 58 52
United Kingdom
SUBSCRIPTION INFO

Percentile Rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Overall Community Employees Environment Governance
AstraZeneca 96% 88% 79% 85% 85%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
United Kingdom
SUBSCRIPTION INFO

Ratings History

Only subscribers can interact with the graph.

More CSR Rating Details

  Community Employees
Community Dev & Philanthropy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
AstraZeneca
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 53 54 55 58 55 55
United Kingdom
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environmant Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
AstraZeneca
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 57 58 57 50 55 51
United Kingdom
SUBSCRIPTION INFO

Percentile rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Community Employees
Community Dev & Philantrophy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
AstraZeneca 88% 76% 91% 76% 56% 92%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
United Kingdom
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environment Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
AstraZeneca 87% 90% 79% 89% 74% 89%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
United Kingdom
SUBSCRIPTION INFO

2 Special Issues Affect This Company (see a list of issues here)

Working Mother-Friendly Military Contractor
# of Sources 10 1
# of co. % of co. # of co. % of co.
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Overall database 46 0.5 756 8.1
United Kingdom
SUBSCRIPTION INFO

CSRHub Has 90 Data Sources (46 Are Currently Active) for This Company

= sources impacting the current ratings
= sources not impacting the current ratings, but included in earlier ratings for this company
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO

Original Data Values

(unsubscribed users can see the list, subscribers can see the data details for most sources)

Data source name

Data source element name Minimum value Value provided by datasource Maximum value Data description
SUBSCRIPTION INFO
annual_sales_local 286 30506265000 2.407451E+11 NA
Emissions per assets 2.8321 0.0007 2.8387656764E-10 NA
Emissions per employee 235484.5 36.5246 0.073 NA
Emissions per sale 4.2576 0.0001 2.7756653992E-07 NA
emissions_total_tco2e 70790000 211581 9 NA
employees_total 1 67953 508714 NA
Harzardous emitter? Yes No No NA
line_of_business Non-life insurance NA
total_assets_local 1000 43526065000 1.506867E+12 NA
waste_hazardous_kg 72001000 0 0 NA
waste_non_hazardous_kg 962755000 0 0 NA
SUBSCRIPTION INFO
Brand Finance 2011-12
SUBSCRIPTION INFO
Brand Value / Enterprise Value (%) -48.164682123 0.0568 316.6056 NA
Brand Value 2012 381.6941 NA
BSI 50 62.1653 88.4717 NA
Domicile BRITAIN NA
Enterprise Value NA 9992.2933 NA NA
Reviewed ? No response NA
Sector Consumer, Non-cyclical NA
SUBSCRIPTION INFO
Brand Value 2014 10 1121.0023 87304 A brand strength is assessed by using our Brand Strength Index framework. This benchmarks the strength, risk and future potential of a brand relative to its competitors by assessing input measures, brand equity measures, and output performance across four
BSI 51.3 76 94.2 NA
Domicile UNITED KINGDOM NA
Sector Consumer, Non-cyclical NA
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
0. Further Information NA NA NA NA
0.1. Introduction - Please give a general description and introduction to your organization. NA AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society. We di NA NA
5.1e Identified climate change risks driven by changes in other climate-related developments? NA Yes NA NA
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA AstraZeneca takes its responsibilities seriously; sustainability has been explicitly integrated into AstraZeneca’s Responsible Business Plan. Key performance indicators and targets have been established for climate change, water and waste (5.1-I). Furthe NA NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6. Attachments NA NA NA NA
6. Further Information NA NA NA NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in regulation; Opportunities driven by changes in other climate-related developments NA NA
6.1a Identified climate change opportunities that are driven by changes in regulation? NA Yes NA NA
6.1b. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA Although no opportunities specific to AstraZeneca have been identified related to regulatory changes, we support the use of regulatory mechanisms to provide an effective framework to encourage industry to participate in the invention, development and use NA NA
6.1c Identified climate change opportunities that are driven by changes in physical climate parameters? NA No NA NA
14. Attachments NA NA NA NA
6.1d. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA NA NA NA
6.1e Identified opportunities that are driven by changes in other climate-related developments? NA Yes NA NA
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA Some of our work relates to the emerging needs identified above (6.1-D & E), including; further developing our respiratory therapy product portfolio for the effective treatment of asthma and chronic obstructive pulmonary disease (COPD); committing resourc NA NA
13. Attachments NA NA NA NA
11. Attachments NA NA NA NA
11. Further Information NA NA NA NA
11.1. Do you consider that the grid average factors used to report Scope 2 emissions in Question 8.3 reflect the contractual arrangements you have with electricity suppliers? NA No NA NA
11.1a. You may report a total contractual Scope 2 figure in response to this question. Please provide your total global contractual Scope 2 GHG emissions figure in metric tonnes CO2e 0 232723 17902000 NA
11.2. Has your organization retired any certificates, e.g. Renewable Energy Certificates, associated with zero or low carbon electricity within the reporting year or has this been done on your behalf? NA Yes NA NA
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No Yes Yes NA
3.2a. Please provide details (see guidance) NA Like other pharmaceutical companies, our carbon footprint is also affected by some of our respiratory therapies, and specifically our pressurised metered dose inhaler (pMDI) products. pMDIs rely on propellants, such as hydrofluoroalkanes (HFAs), to delive NA NA
3.3c Number of methods used to drive investment in emissions reduction activities. 0 3 12 NA
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Financial optimization calculations, Lower return on investment (ROI) specification, Marginal abatement cost curve NA NA
5. Attachments NA NA NA NA
5. Further Information NA NA NA NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in regulation; Risks driven by changes in physical climate parameters; Risks driven by changes in other climate-related developments NA NA
5.1a Identified risks driven by changes in regulation? NA NA NA NA
5.1b. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA Since we are already actively managing our climate change position, we do not foresee any existing or reasonably foreseeable regulatory initiatives making any significant additional constraints on our operations. The increasing focus on supply chain acc NA NA
14. Further Information NA NA NA NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Individual/Sub-set of the Board or other committee appointed by the Board Individual/Sub-set of the Board or other committee appointed by the Board NA
1.1a. Please identify the position of the individual or name of the committee with this responsibility NA Professor Dame Nancy Rothwell, a Non-Executive Director, is responsible for overseeing the setting and implementation of our Responsible Business strategy, including climate change, on behalf of the AstraZeneca Board. The Board owns our Responsible Bus NA NA
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes NA
13. Further Information NA NA NA NA
13.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Increased Decreased Decreased NA
13.1a (i) If absolute emissions (Scope 1 and 2 combined) have increased, decreased or remained the same overall compared to the previous year, state direction of change NA Moderately Decreased NA NA
13.1a (ii) If absolute emissions (Scope 1 and 2 combined) have increased, decreased or remained the same overall compared to the previous year, state the reason for the direction of change NA Decrease: Divestment, Decrease: Emissions reduction activities NA NA
13.1a (iii) If emissions have increased, decreased or remained the same overall, provide the emissions value (%) NA Decrease: , Increase: 5.4 , Emission value for which direction is not stated: NA NA
2012 Score 0 73 100 NA
2012 Performance Band E B A NA
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA We engage through various trade associations, such as the ICC Commission on Environment Climate Change Task force; engagement fora, such as the UN Global Compact; contact groups, such as the SustainAbility/Globescan Pulse network; and directly with policy NA NA
8.8. Are carbon dioxide emissions from the combustion of biologically sequestered carbon (i.e. carbon dioxide emissions from burning biomass/biofuels) relevant to your company? No No Yes NA
8.8a. Please provide the emissions in metric tonnes CO2e 0.01 NA 27263000 NA
Management 4. Attachments NA https://www.cdproject.net/Sites/2012/04/1104/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/4.Communication/Business review - delivering our strategy.pdf NA NA
Management 4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? NA 3 NA NA
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA Since we are already actively managing our climate change risk position, we do not foresee any existing or reasonably foreseeable physical impacts making any significant additional constraints on our operations. The increasing focus on supply chain acco NA NA
2. Attachments NA NA NA NA
2. Further Information NA NA NA NA
5.1c Identified climate change risks driven by change in physical climate parameters? NA Yes NA NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA Integrated into multi-disciplinary company wide risk management processes NA NA
2.1a. Please provide further details (see guidance) NA Our worldwide activities put AstraZeneca in the global spotlight on a diverse range of issues that affect or concern our stakeholders and society, including climate change. We know that effective management of these issues is critical to maintaining trust NA NA
2.2. Is climate change integrated into your business strategy? No Yes Yes NA
2.2a. Please describe the process and outcomes (see guidance) NA We strive to ensure that sound risk management is embedded within our strategy, planning, budgeting and performance management processes. Annually, the Group develops a long-term business plan to support the delivery of its strategy which the Board review NA NA
2.2b. Please explain why not NA NA NA NA
2.3. Do you engage with policy makers to encourage further action on mitigation and/or adaptation? No Yes Yes NA
3. Attachments NA NA NA NA
3. Further Information NA NA NA NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute and intensity targets Absolute and intensity targets NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years Yes Yes NA
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No No Yes NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA The physical changes associated with climate change will inevitably change the way AstraZeneca sources, markets and distributes its drug products. There are no significant opportunities presented in the most likely climate change scenarios that are antic NA NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
7. Attachments NA https://www.cdproject.net/Sites/2012/04/1104/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/7.EmissionsMethodology/AZ EF 2011.xls NA NA
7. Further Information NA Please see attached spreadsheet "AZ EF 2011.xls" for emission factor list. NA NA
7.1. Please provide your base year and base year emissions (Scopes 1 and 2) NA NA NA NA
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. NA USD($) NA NA
1. Attachments NA NA NA NA
1. Further Information NA NA NA NA
8.7. Please indicate the verification/assurance status that applies to your Scope 2 emissions More than 0% but less than or equal to 20% NA More than 90% but less than or equal to 100% NA
11.1b. Explain the basis of the alternative figure (see guidance) The contractual Scope 2 figure differs from the Gross Scope 2 figure provided in answer to Q10.1a in respect to: 1. Entering into a voluntary low-carbon tariff with our UK electricity supplier, 2. Purchase of Renewable Energy Certificates in the USA cove NA
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? We are managing emissions from our sites inside the EU Emissions Trading Scheme so that we will not be a net purchaser of allowances. We have been able to sell a small net surplus allocation and the proceeds were reinvested in energy efficiency in our fac NA
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA NA NA NA
8.2a. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e 92 NA 231902967 NA
8.3a. Please provide your gross global Scope 2 emissions figure in metric tonnes CO2e 293 NA 8071070 NA
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA Yes NA NA
8.6. Please indicate the verification/assurance status that applies to your Scope 1 emissions More than 0% but less than or equal to 20% NA More than 90% but less than or equal to 100% NA
SUBSCRIPTION INFO
8.7. Please indicate the verification/assurance status that applies to your Scope 2 emissions Third party verification or assurance complete Proportion of Scope 2 emissions that are verified/assured for 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.7a. Please indicate the proportion of your Scope 2 emissions that are verified/assured More than 0% but less than or equal to 20% More than 90% but less than or equal to 100% More than 90% but less than or equal to 100%
8.7b Reporting Period From/To/Please provide further details of the verification/assurance undertaken, and attach the relevant statements/Type of verification or assurance/Relevant standard/Attach the document No Response
8.8. Are carbon dioxide emissions from biologically sequestered carbon relevant to your organization? No
8.8a. Please provide the emissions in metric tonnes CO2 NA
8.8a. Please provide the emissions in metric tonnes CO2e 0.05 NA 13638000
9.1. Do you have Scope 1 emissions sources in more than one country? Yes
9.1a Reporting Period From/To/Please complete the table below: Country/Region/Scope 1 metric tonnes CO2e 1 Jan 2012/31 Dec 2012/United Kingdom/137700
9.2. Please indicate which other Scope 1 emissions breakdowns you are able to provide (tick all that apply) NA By activity NA
9.2a Reporting Period From/To/Please break down your total gross global Scope 1 emissions by business division: Business division/Scope 1 emissions (metric tonnes CO2e) No Response
9.2b Reporting Period From/To/Please break down your total gross global Scope 1 emissions by facility: Facility/Scope 1 emissions (metric tonnes CO2e) No Response
9.2c Reporting Period From/To/Please break down your total gross global Scope 1 emissions by GHG type: GHG type/Scope 1 emissions (metric tonnes CO2e) No Response
9.2d Reporting Period From/To/Please break down your total gross global Scope 1 emissions by activity: Activity/Scope 1 emissions (metric tonnes CO2e) No Response
9.2e Reporting Period From/To/Please break down your total gross global Scope 1 emissions by legal structure: Legal structure/Scope 1 emissions (metric tonnes CO2e) No Response
0.3. Country list configuration India
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. USD($)
0.4. Please select the currency in which you would like to submit your response. USD($)
0.5. Please select if you wish to complete a shorter information request. NA
0.6. Modules NA As part of the Investor CDP information request, electric utilities, companies with electric utility activities or assets, companies in the automobile or auto component manufacture sectors and companies in the oil and gas industry should complete suppleme
1. Attachments NA NA NA
1. Further Information NA NA NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Individual/Sub-set of the Board or other committee appointed by the Board Individual/Sub-set of the Board or other committee appointed by the Board
1.1a. Please identify the position of the individual or name of the committee with this responsibility NA Professor Dame Nancy Rothwell, a Non-Executive Director, is responsible for overseeing the setting and implementation of our Responsible Business strategy on behalf of the AstraZeneca Board. Rudy Markham, who is also a Non-Executive Director, has respons NA
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes
1.2a. Who is entitled to benefit from these incentives? All employees/Monetary reward/Remuneration of all staff, including senior management, is assessed on the basis of attainment of targets. Management of climate change issues is incentivised to the extent that our climate change objectives are included in t
10.1. Do you have Scope 2 emissions sources in more than one country? Yes
10.1a Reporting Period: From/To/Please complete the table below: Country/Region/Scope 2 metric tonnes CO2e/Purchased and consumed electricity, heat, steam or cooling (MWh)/Purchased and consumed low carbon electricity, heat, steam or cooling (MWh) 1 Jan 2012/31 Dec 2012/United Kingdom/46800/104200/50000
10.2. Please indicate which other Scope 2 emissions breakdowns you are able to provide (tick all that apply) NA By activity NA
10.2a Reporting Period From/To/Please break down your total gross global Scope 2 emissions by business division: Business division/Scope 2 emissions (metric tonnes CO2e) No Response
10.2b Reporting Period From/To/Please break down your total gross global Scope 2 emissions by facility: Facility/Scope 2 emissions (metric tonnes CO2e) No Response
10.2c Reporting Period: From/To/Please break down your total gross global Scope 2 emissions by activity: Activity/Scope 2 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Imported electricity/262600
10.2d Reporting Period: From/To/Please break down your total gross global Scope 2 emissions by legal structure: Legal structure/Scope 2 emissions (metric tonnes CO2e) No Response
11. Attachments NA NA NA
11. Further Information NA NA NA
11.1. What percentage of your total operational spend in the reporting year was on energy? More than 0% but less than or equal to 5% More than 0% but less than or equal to 5% More than 95% but less than or equal to 100%
11.2. Please state how much fuel, electricity, heat, steam, and cooling in MWh your organization has purchased and consumed during the reporting year: Energy type/MWh Fuel/1023600;Electricity/757600;Heat/84900;Steam/87100;Cooling/0
11.3. Please complete the table by breaking down the total "Fuel" figure entered above by fuel type: Fuels/MWh Residual fuel oil/0
11.4. Please provide details of the electricity, heat, steam or cooling amounts that were accounted at a low carbon emission factor: Basis for applying a low carbon emission factor/MWh associated with low carbon electricity, heat, steam or cooling Supplier specific, backed by instruments/58500
12. Attachments NA
12. Further Information NA
12.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Decreased
12.1a Reason of change Emissions reduction activities, Divestment, Acquisitions, Mergers, Change in output, Change in methodology, Change in boundary, Change in physical operating conditions, Unidentified, Other
12.1a. Reason: Emissions value (percentage) Emissions reduction activities: 6/Divestment: 5/Change in output: 3/
12.2. Please describe your gross combined Scope 1 and 2 emissions for the reporting year in metric tonnes CO2e per revenue: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 22.4/metric tonnes CO2e/3/Increase/A 14% decrease in gross Scope I & II emissions was offset by a 17% decline in group revenue.
12.3. Please describe your gross combined Scope 1 and 2 emissions for the reporting year in metric tonnes CO2e per FTE: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 11.2/metric tonnes CO2e/6/Decrease/A 14% decrease in gross Scope I & II emissions was offset by an 8% decline in group employee numbers.
12.4. Please provide an additional intensity (normalized) metric that is appropriate to your business operations: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change No response
13.1. Do you participate in any emissions trading schemes? Yes
13.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? We are managing emissions from our sites inside the EU Emissions Trading Scheme so that we will not be a net purchaser of allowances. We have been able to sell a small net surplus allocation and the proceeds were reinvested in energy efficiency in our fac
13.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No
14. Attachments NA NA NA
14. Further Information NA NA NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years Yes Yes
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? We are managing emissions from our sites inside the EU Emissions Trading Scheme so that we will not be a net purchaser of allowances. We have been able to sell a small net surplus allocation and the proceeds were reinvested in energy efficiency in our fac
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No No Yes
14.2. Please indicate the verification/assurance status that applies to your Scope 3 emissions Third party verification or assurance complete
14.2a. Please indicate the proportion of your Scope 3 emissions that are verified/assured More than 90% but less than or equal to 100%
14.3. Are you able to compare your Scope 3 emissions for the reporting year with those for the previous year for any sources? Yes
14.4. Do you engage with any of the elements of your value chain on GHG emissions and climate change strategies? (Tick all that apply) Yes, our suppliers; Yes, our customers
14.4a. Please give details of methods of engagement, your strategy for prioritizing engagements and measures of success With significant externalisation of manufacturing activity in line with our business strategy we recognise the importance of working with suppliers to ensure they have ethical standards that are consistent with our own. This incorporates setting environme
14.4d. Please explain why not and any plans you have to develop an engagement strategy in the future NA
2. Attachments NA NA NA
2. Further Information NA NA NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA Integrated into multi-disciplinary company wide risk management processes NA
2.1a. Please provide further details Our worldwide activities put AstraZeneca in the global spotlight on a diverse range of issues that affect or concern our stakeholders and society, including climate change. We know that effective management of these issues is critical to maintaining trust
2.1a. Please provide further details (see guidance) NA Our worldwide activities put AstraZeneca in the global spotlight on a diverse range of issues that affect or concern our stakeholders and society, including climate change. We know that effective management of these issues is critical to maintaining trust NA
2.2. Is climate change integrated into your business strategy? No Yes Yes
2.2a. Please describe the process and outcomes We strive to ensure that sound risk management is embedded within our strategy, planning, budgeting and performance management processes. Annually, the Group develops a long-term business plan to support the delivery of its strategy which the Board review
2.2a. Please describe the process and outcomes (see guidance) NA We strive to ensure that sound risk management is embedded within our strategy, planning, budgeting and performance management processes. Annually, the Group develops a long-term business plan to support the delivery of its strategy which the Board review NA
2.2b. Please explain why not NA NA NA
2.3. Do you engage in activities that could either directly or indirectly influence policy on climate change through any of the following? (tick all that apply) Yes
2.3. Do you engage with policy makers to encourage further action on mitigation and/or adaptation? No Yes Yes
2.3a. On what issues have you been engaging directly?: Focus of legislation/Corporate Position/Details of engagement/Proposed solution Mandatory carbon reporting/Support/We engaged directly with DEFRA and via the Institute of Environmental Management and Assessment to help shape the DEFRA guidance supporting the Regulations to be laid before UK Parliament in may/June 2013./Minor amendmen
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA We engaged directly with DEFRA and via the Institute of Environmental Management and Assessment to help shape the DEFRA guidance supporting the Regulations to be laid before UK Parliament in may/June 2013., We have engaged with the WRI on their GHG Protoc NA
2.3b. Are you on the Board of any trade associations or provide funding beyond membership? Yes
2.3c. Please enter the details of those trade associations that are likely to take a position on climate change legislation/Trade association IPAC/Consistent/IPAC supports the responsible use of HFCs for pharmaceutical delivery devices only where cost-effective and technically feasible alternatives are not available./No change.
2.3d. Do you publically disclose a list of all the research organizations that you fund? NA
2.3e. Do you fund any research organizations to produce public work on climate change? NA
2.3f. Please describe the work and how it aligns with your own strategy on climate change NA
2.3g. Please provide details of the other engagement activities that you undertake NA
2.3h. What processes do you have in place to ensure that all of your direct and indirect activities that influence policy are consistent with your overall climate change strategy? All of the engagements we have undertaken comply with our Code of Conduct: http://www.astrazeneca.com/Responsibility/Code-policies-standards/Code-of-Conduct
2.3i. Please explain why you do not engage with policy makers NA
3. Attachments NA https://www.cdproject.net/sites/2013/04/1104/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/3.TargetsandInitiatives/Global Carbon MACC.pptx NA
3. Further Information NA NA NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute and intensity targets Absolute and intensity targets
3.1a. Absolute target/ID/Scope/% of emissions in scope/% reduction from base year/Base year/Base year emissions (metric tonnes CO2e)/Target year/Comment 3.1.1/Scope 1+2+3/100/20/2010/964000/2015/Base year emissions have been recalculated from those disclosed in 2012, due to incorporation of our biologics business, MedImmune, in the overall Safety, Health and Environment strategy and objectives process.
3.1b. Intensity target/ID/Scope/% of emissions in scope/% reduction from base year/Metric/Base year/Normalized base year emissions/Target year/Comment 3.1.2/Other: Scope 1 & 2 emissions from facility (site) energy use/100/30/Other: To support our overall absolute carbon reduction target (3.1.1, above), we have targeted a 30% improvement in facility energy efficiency (measured across the group as MWh per
3.1c. What change in absolute emissions this intensity target reflects/ID/Direction of change anticipated in absolute Scope 1+2 emissions at target completion?/% change anticipated in absolute Scope 1+2 emissions 3.1.2/Decrease/22/No change/0/
3.1d. Please provide details on your progress against this target made in the reporting year/ID/% complete (time)/% complete (emissions)/Comment 3.1.1/40/70/This will primarily be delivered through the three targets below, 3.1.2 to 3.1.4, and is largely on track at this early stage in its delivery.
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No Yes Yes
3.2a. Please provide details (see guidance) NA Like other pharmaceutical companies, our carbon footprint is also affected by some of our respiratory therapies, and specifically our pressurised metered dose inhaler (pMDI) products. pMDIs rely on propellants, such as hydrofluoroalkanes (HFAs), to delive NA
3.3. Did you have emissions reduction initiatives that were active within the reporting year (this can include those in the planning and/or implementation phases) No Yes Yes
3.3a. Please identify the total number of projects at each stage of development, and for those in theimplementation stages, the estimated CO2e savings/Stage of development/3.3a. Number of projects/Total estimated annual CO2e savings in metric tonnes CO2e Under investigation/3/20000
3.3c Number of methods used to drive investment in emissions reduction activities. 0 3 13 Number of methods used to drive investment in emissions reduction activities.
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Financial optimization calculations, Lower return on investment (ROI) specification, Marginal abatement cost curve NA
3.3c. What methods do you use to drive investment in emissions reduction activities?/Comment Financial optimization calculations/
4. Attachments NA
4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? - Further Information NA
4.1. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? 4 The number of corporate annual reports and voluntary publications (complete and/or underway) made about the company’s response to climate change and GHG emissions performance
5. Attachments NA NA NA
5. Further Information NA NA NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in regulation; Risks driven by changes in physical climate parameters; Risks driven by changes in other climate-related developments NA
5.1a. Climate change risks driven by changes in regulation Yes
5.1a. Please describe your risks driven by changes in regulation /ID/Risk driver/ Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact 5.1-A/International agreements/The successor agreement to the Kyoto Protocol under the UNFCCC remains far from providing a workable framework for clear national and regional direction. Evolution of the EU ETS and its linkages to other existing or future s
5.1b. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk and (iii) the costs associated with these actions Unmitigated cost at risk from the CO2 emissions we have under the EU ETS would be $600k and $140k under the UK CRC scheme (5.1-B). These figures assume all emissions are at risk and indicative carbon prices of $5.67 per tonne for EU ETS allowances and $18
5.1c. Climate change risks driven by change in physical climate parameters Yes
5.1c. Please describe your risks that are driven by change in physical climate parameters/ID/Risk driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact 5.1-E/Change in precipitation pattern/Water resources may become increasingly limited in the face of climate change. Two facilities, representing about 3% of the total amount of water we use globally, are located in countries with water resources currentl
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA Potential unmitigated risk to revenues from weather-induced supply disruption is estimated to reach 1% of total revenue, assuming total loss of production from our supply sites located in water-stressed areas; up to approx. $250m against 2012 group revenu NA
5.1e. Please describe your risks that are driven by changes in other climate-related developments/ID/Risk driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact /Change in precipitation pattern/Climate changes (temperature and rainfall, mostly) can affect telecommunications resources such as those that use satellites, can destroy the physical cabling and the power outages./Increased operational cost/Unknown/Direc
5.1e.Climate change risks driven by changes in other climate-related developments Yes
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA Unmitigated reputational risk (5.1-I) could impact the credit quality and equity value of the company. Given that AstraZeneca has a relatively modest carbon intensity, this is estimated to be up to 0.5% of equity value ($200m at a market cap of $40bn).Ast NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6. Attachments NA NA NA
6. Further Information NA NA NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in regulation; Opportunities driven by changes in other climate-related developments NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? -Transparency Yes
6.1a Identified climate change opportunities that are driven by changes in regulation? NA Yes NA
6.1a. Please describe your opportunities that are driven by changes in regulation/ID/Opportunity driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact 6.1-A/International agreements/We believe that the most effective response to the challenges associated with climate change can only be achieved through a concerted global effort. The world community should, through the UNFCCC, pursue an appropriate and c
6.1b. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity and (iii) the costs associated with these actions Although no opportunities specific to AstraZeneca have been identified related to regulatory changes, we support the use of regulatory mechanisms to provide an effective framework to encourage industry to participate in the invention, development and use
6.1d. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity and (iii) the costs associated with these actions NA
6.1e. Please describe the opportunities that are driven by changes in other climate-related developments Yes
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA Some of our work relates to the emerging needs identified above (6.1-D & E), including; further developing our respiratory therapy product portfolio for the effective treatment of asthma and chronic obstructive pulmonary disease (COPD); committing res NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA The physical changes associated with climate change will inevitably change the way AstraZeneca sources, markets and distributes its drug products. However, given the nature of the pharmaceutical sector and our business focus on discovery, development and NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
7. Attachments NA https://www.cdproject.net/sites/2013/04/1104/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/7.EmissionsMethodology/AZ EF 2012.xls NA
7. Further Information NA NA NA
7.1. Please provide your base year and base year emissions (Scopes 1 and 2)/7.1. Base year From Date:/To Date:/ Scope 1 Base year emissions (metric tonnes CO2e)/N39Scope 2 Base year emissions (metric tonnes CO2e) 2010-01-01/2010-12-31/417700/359100
7.2. Please give the name of the standard, protocol or methodology you have used to collect activity data and calculate Scope 1 and Scope 2 emissions NA The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition) NA
7.3. Please give the source for the global warming potentials you have used Gas/Reference CO2/IPCC Fourth Assessment Report (AR4 - 100 year)
7.4. Please give the emissions factors you have applied and their origin; alternatively, please attach an Excel spreadsheet with this data Fuel/Material/Energy/Emission Factor/Unit/Reference ///Please see attached spreadsheet "AZ EF 2012.xls" for emission factor list.
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA Financial control NA Boundary used for Scope 1 and 2 greenhouse gas inventory during 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e NA Gross global Scope 1 emissions figure in metric tonnes CO2e for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figures in metric tonnes CO2e 340800
8.3. Please provide your gross global Scope 2 emissions figures in metric tonnes CO2e NA
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA No NA Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.4a Reporting Period From/To/Source/Scope/Explain why the source is excluded No Response
8.5 Reporting Period From/To/Please estimate the uncertainty of the total gross global Scope 1 and 2 emissions figures that you have supplied and specify the sources of uncertainty in your data gathering, handling and calculations/Scope 1 emissions No Response
8.6. Please indicate the verification/assurance status that applies to your Scope 1 emissions Third party verification or assurance complete Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.6a. Please indicate the proportion of your Scope 1 emissions that are verified/assured More than 0% but less than or equal to 20% More than 90% but less than or equal to 100% More than 90% but less than or equal to 100%
8.6b Reporting Period From/To/Please provide further details of the verification/assurance undertaken, and attach the relevant statements: Type of verification or assurance/Attach the document No Response
2013 Performance Band E B A NA
2013 Score 0 85 100 NA
0. Attachments NA NA NA If you have not been presented with a sector module that you consider would be appropriate for your company to answer, please select the module below. If you wish to view the questions first, please see https://www.cdproject.net/en-US/Programmes/Pages/Mor
0. Further Information NA NA NA If you are in these sectors (according to the Global Industry Classification Standard (GICS)), the corresponding sector modules will be marked as default options to your information request. If you want to query your classification, please email respond@c
0.1. Introduction - Please give a general description and introduction to your organization. NA AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society. We di NA
0.1. Please give a general description and introduction to your organization. AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society. We di
0.2. Please state the start and end date of the year for which you are reporting data. 2012-01-01
SUBSCRIPTION INFO
2.1. Are you able to identify which of your operations are located in water-stressed regions? No Response 4 answers 4 answers NA
0.4. Exclusions Are there any geographies, activities, facilities or types of water inputs/outputs within this boundary which are not included in your disclosure? NA Yes NA NA
2.2b. You may explain here why you are not able to identify which of your operations are located in regions subject to water stress or water-related risk and whether you have plans to explore this issue in the future No Response 3 answers 3 answers NA
0.4aList of Exclusions & Reason for Exclusions-Transparency & Reporting No Response Answered Answered NA
1.1. Does your company have a water policy, strategy or management plan? No Yes Yes NA
2.1bPlease list the water-stressed regions where you have operations and the percentage of your total operations in that area NA India/Bangalore/1 – 10Egypt/Cairo/1 – 10 NA NA
2.1bPlease list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting No Response 3 answers 4 answers NA
2.2. Do you use other indicators (besides water stress) to identify operations which are located in regions subject to water-related risk? NA NA NA NA
0.1. Introduction Please give a general description and introduction to your organization. NA AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society. NA NA
0.2. Reporng Year Please state the start and end date of the year for which you are reporting data. 2.0. Enter the period that will be disclosed. NA 01-01-2011 - 31-12-2011 NA NA
0.3. Reporting Boundary Please indicate the category that describes the company, entities, or group for which you are reporting. NA Companies, entities or groups over which financial control is exercised. NA NA
2.3. Please specify the total percentage of your operations that are located in the regions at risk which you identified in questions 2.1 and/or 2.2 NA Yes NA NA
2.4. Please specify the basis you use to calculate the percentages used for questions 2.1 and/or 2.2 NA FAO/AQUASTAT NA NA
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting Australia/CCA's Water Policy covers all aspects of water related operations activities from both municipal and groundwater sources across the beverage and food businesses. Global/For AstraZeneca facilities there is a commitment to make sure water use is known, minimised and efficiently managed and has little impact on the local environment. AstraZeneca is committed to managing supply chain emissions responsibly: seeking t United States of America/We have a philosophy to limit water waste and a strategy to identify reduction opportunities from development through operations through supply chain. We build our stores to green building standards (LEED and Green Globes), and e NA
1.1b. Does the policy, strategy or plan specify water reduction, quality or efficiency targets or other water-related goals? NA Global NA NA
1.1bDoes the water policy, strategy or plan specify water-related targets or goals? No Yes Yes NA
0.4aList of Exclusions & Reason for Exclusions NA MedImmune/AstraZeneca's water use data includes data from MedImmune for 2011. Data from MedImmune is excluded prior to 2011and work is ongoing to include other water data parameters that are still excluded in 2011, such as wastewater output. MedImmune is NA NA
SUBSCRIPTION INFO
0.2. Reporting Year 2012-01-01
0.3. Reporting Boundary Companies, entities or groups over which financial control is exercised
0.4. Are there any geographies, activities, facilities or types of water inputs/outputs within this boundary which are not included in your disclosure? Yes
0.4a. List of Exclusions & Reason for Exclusions-Transparency & Reporting 2 answers
0.4a. List of Exclusions & Reason for Exclusions-Transparency & Reporting (value) #NAME?
1.1. Does your company have a water policy, strategy or management plan? No Yes Yes
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting Australia/CCA's Water Policy covers all aspects of water related operations activities from both municipal and groundwater sources across the beverage and food businesses. 2 answers United States of America/We have a philosophy to limit water waste and a strategy to identify reduction opportunities from development through operations through supply chain. We build our stores to green building standards (LEED and Green Globes), and e
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting (value) Company-wide/Our strategy for water was developed in 2010 and is reviewed regularly. Our strategy covers the period from 2011 to 2020 and supports our objective to minimise the environmental impact of our operations and activity by reducing the carbon foo
1.1b. Does the water policy, strategy or plan specify water-related targets or goals? Yes
1.1c. Description of Target/goal, its type and geographical reach -Transparency & Reporting 3 answers
1.1c. Description of Target/goal, its type and geographical reach -Transparency & Reporting (value) #NAME?
1.1d. You may explain here why your company does not have a water policy, strategy or plan and if you intend to put one in place. NA
1.2. What specific actions has your company taken to manage water resources or engage stakeholders in water-related issues and what are their outcomes?-Transparency & Reporting 2 answers
1.2. What specific actions has your company taken to manage water resources or engage stakeholders in water-related issues and what are their outcomes?-Transparency & Reporting (value) #NAME?
2.1. Are any of your operations located in water-stressed regions? Yes
2.1a. Please specify the method(s) you use to characterize water-stressed regions- Environmental policy & Reporting FAO/AQUASTAT
2.1a. Please specify the method(s) you use to characterize water-stressed regions- Environmental policy & Reporting (value) #NAME?
2.1b. Please list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting 2 answers
2.1b. Please list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting (value) #NAME?
2.2. Are there other indicators (besides water stress) which you wish to report that help you to identify which of your operations are located in regions subject to water-related risk? No
2.2a. Please list the relevant risk indicator of your total operations in that area-Environment Policy and Reporting NA
2.2b. You may explain here why you do not wish to report or why you do not use other indicators to identify which of your operations are located in regions subject to water-related risk. We believe that water stress is the most appropriate indicator for assessing water-related risk at our facilities.
2.3. Please specify the total proportion of your operations that are located in the regions at risk which you identified in questions 2.1 and/or 2.2. 0 3 99
2.4. The basis to use to calculate the percentages used for questions 2.1 and/or 2.2 2 answers
2.4. The basis to use to calculate the percentages used for questions 2.1 and/or 2.3 (value) #NAME?
2.5. Do any of your key inputs or raw materials (excluding water) come from regions subject to water-related risk? No
2.5a. Please state or estimate the percentage of your key water-intensive inputs (excluding water) that come from these regions-Transparency & Reporting NA
2.5b. You may explain here why you are not able to identify if any of your key inputs or raw materials come from regions subject to water-related risk and whether you have plans to explore this issue in the future. NA
3.1. Is your company exposed to water-related risks (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? No
3.1a. Please describe the current and/or future risks to your operations, the ways in which these risks affect or could affect your operations and your current or proposed strategies for managing them-Transparency & Reporting NA
3.1a. Please describe the current and/or future risks to your operations, the ways in which these risks affect or could affect your operations and your current or proposed strategies for managing them-Transparency & Reporting (value) NA
3.1b. Please explain why you do not consider your company to be exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure. Although we recognise risk to our manufacturing operations in water stressed areas, we do not believe that management of this risk will require substantive change to our business operations, due to the flexible and responsive design of our supply capabili
3.1c. Please explain why you do not know if your company is exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure, and your plans to assess this risk in the future. NA
3.2. Country or geographical scale-Environment Policy & Reporting Facility
3.2. What methodology do you use to analyze water-related risk across your operations?-Transparency & Reporting Answered
3.2. What methodology do you use to analyze water-related risk across your operations? Assess loss of makeup water for cooling from any source to the critical cooling systems
3.3. Do you require your key suppliers to report on their water use, risks and management? Yes
3.4. Is your supply chain exposed to water-related risks (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? No
3.4b. Please explain why you do not consider your supply chain to be exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure. New suppliers are sourced through our global sourcing and supplier management framework, which incorporates a set of Responsible Procurement tools and standards. The framework also incorporates a risk based approach for identifying how we communicate our
3.4c. Please explain why you do not know if your supply chain is exposed to water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure, and your plans to assess this risk in the future. NA
4.1. Has your business experienced any detrimental impacts related to water in the past five years? No
4.1. Please describe any detrimental impacts to business related to water your company has faced in the past five years, their financial impacts and whether they have resulted in any changes to company practices- Transparency & Reporting Answered
5.1. Do water-related issues present opportunities (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? No
5.1a. Please describe the current and/or future opportunities, the ways in which these opportunities affect or could affect your operations and your current or proposed strategies for exploiting them-Environmental Policy & Reporting NA
5.1a. Please describe the current and/or future opportunities, the ways in which these opportunities affect or could affect your operations and your current or proposed strategies for exploiting them-Environmental Policy & Reporting (value) NA
5.1b. Please explain why you do not consider water-related issues to present opportunities to your company that have the potential to generate a substantive change in your business operation, revenue or expenditure or supply chain. Although no opportunities specific to AstraZeneca have been identified related to water, we support the use of policy and regulatory mechanisms to provide an effective framework to encourage industry to participate in the invention, development and use of
5.1c. Please explain why you do not know whether water-related issues present opportunities to your company that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
6.1. Has your company identified any linkages or trade-offs between water and carbon emissions in its operations or supply chain? Yes
6.1a. Please describe the linkages or trade-offs between water and carbon emissions in its operations or supply chain?--Transparency & Reporting 2 answers
6.1a. Please describe the linkages or trade-offs and the related management policy or action between water and carbon emissions in its operations or supply chain?-Transparency & Reporting (value) #NAME?
7.1. Are you able to provide data, whether measured or estimated, on water withdrawals within your operations? Yes
7.1a. Please report the water withdrawals within your operations for the reporting year-Transparency & Reporting 0
7.1a. Please report the water withdrawals within your operations for the reporting year-Transparency & Reporting (value) 0
7.1b. Please explain why you are not able to provide data for water withdrawals. NA
7.2. Are you able to provide data, whether measured or estimated, on water recycling/reuse within your operations? No
7.2a. Please report the water recycling/reuse within your operations for the reporting year-Transparency & Reporting NA
7.2a. Please report the water recycling/reuse within your operations for the reporting year-Transparency & Reporting (value) NA
7.2b. Please explain why you are not able to provide data for water recycling/reuse within your operations. Performance metrics on water reuse or recycling rates is not collected in our global corporate safety, health and environmental reporting system
7.2b. Please explain why you are not able to provide data for water recycling/reuse within your operations-Transparency & Reporting Answered
7.3. Please use this space to describe the methodologies used for questions 7.1 and 7.2 or to report withdrawals or recycling/reuse in a different format to that set out above. Safety, health and environmental data are received from all parts of AstraZeneca quarterly by the AZSHE department. Each facility is required to report performance against a set of criteria defined in a global reporting procedure. Water metrics collected
7.3. Please use this space to describe the methodologies used for questions 7.1 and 7.2 or to report withdrawals or recycling/reuse in a different format to that set out above-Transparency & Reporting Answered
7.4. Are any water sources significantly affected by your company's withdrawal of water? No
7.4a. Please list any water sources significantly affected by your company's withdrawal of water. NA
7.4b. You may explain here why your company's withrawal of water does not significantly affect any water sources. 97% of our water use occurs in locations which are not subject to water stress
7.4b. You may explain here why your company's withrawal of water does not significantly affect any water sources-Transparency & reporting Answered
7.4c. Please explain why you do not know if any water sources are significantly affected by your company's withdrawal of water. NA
8.1. Are you able to identify discharges of water from your operations by destination, by treatment method and by quantity and quality using standard effluent parameters? Yes
8.1a. Please explain why you are not able to identify discharges from your operations by destination, treatment method , quantity and quality, and whether you have any plans to put in place systems that would enable you to do so. NA NA
8.2. Did your company pay any penalties or fines for significant breaches of discharge agreements or regulations in the reporting period? No NA
8.2a. Please describe the quality, quantity and destination of the water that was the subject of the significant breach(es), the associated fines and any actions taken to minimise the risk of future non-compliance NA NA
8.3. Are any water bodies and related habitats significantly affected by discharges of water or runoff from your operations? No NA
8.3a. Please list any water bodies and related habitats which are significantly affected by discharge of water or runoff from your operations NA NA
8.3b. You may explain here why your company's discharge of water does not significantly affect any water bodies or associated habitats. Sites discharge waste water under local permit conditions to wastewater treatment works. In 2011 there were two breaches of conditions that were reported to the local authorities. These minor breaches did not significantly affect any water bodies or as NA
8.3b. You may explain here why your company's discharge of water does not significantly affect any water bodies or related habitats-Tansparency & Reporting Answered NA
8.3c. Please explain why you do not know if any water bodies and associated habitats are significantly affected by discharge of water or runoff from your operations. NA NA
9.1. Please provide any available financial intensity values for your company's water use across its operations 3 answers NA
9.1. Please provide any available financial intensity values for your company's water use across its operations (value) #NAME? NA
9.2. Please provide any available water intensity values for your company's products or services across its operations. #NAME? NA
Please enter the name of the individual that has signed off (approved) the response and their job title Mr Steve Rumford, Global Head of Environment NA
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Reduce 0 40 52 NA
Report 0 10 12 NA
Review 0 21 27 NA
SUBSCRIPTION INFO
Rank by Context-Based Score (1 to 100) 100 48 1 Climate counts rank
Sustainable N Y Y If a company has a score of less than or equal to one (?1), it is considered “sustainable”, whereas a company with a score greater than one (>1) is considered “unsustainable”
SUBSCRIPTION INFO
2011 Electricity Usage /MWh 35 873418 272242310 Annual electricity consumption resulting from all operations within the defined boundaries of a given organisation.
2011 Renewables Usage /MWh 5 5259 20498400 Total number of MWh of electricity or proxy purchased globally from renewable energy power-generating projects directly or indirectly.
Biomass/Biofuel (%) 0 0 100 Biomass = woody waste; agricultural crops or waste; animal and other organic waste; energy crops; co-firing of biomass in fossil fuel generation plants. Biofuel = biofuels such as bioethanol and biodiesel.
Blend (%) 0 0 100 Blend = renewable electricity consisting of a mix of renewables as provided by for example third-party marketers.
Country UK NA
Geothermal (%) 0 0 79 Geothermal = all electricity from geothermal facilities.
Global CREX rank 1 244 280 The CREX participants are ranked based on the percentage of renewable electricity procured for their own use in 2011, calculated by dividing renewable electricity consumption by total electricity consumption for the period.
Hydro (%) 0 0 100 Hydro = hydro projects from new generation capacity.
Sector Health Care NA ICB system top-level industry designation (via the Bloomberg Terminal).
Solar (%) 0 100 100 Solar = all electricity produced solar photovoltaics (PV) and solar thermal facilities.
Unknown (%) 0 0 100
Waste to energy (%) 0 0 100 Waste-to-energy = electricity using landfill gas or waste from other facilities such as wastewater treatment stations.
Wind (%) 0 0 100 Wind = all electricity from wind turbines.
SUBSCRIPTION INFO
Reported Scope 3 Total (tCO2e) 670000000 470000 0 Indicated the total reported Scope 3 (all other indirect emissions) of the company in metric tonnes of CO2 equivalent (tCO2e) as defined by the Greenhouse Gas Protocol. Where no Scope 3 emissions are reported, this is recorded as "No Data"
Scope 1+2 Intensity 11162.43 20.63 0.3 Intensity is calculated by adding together a company's Scope 1 and Scope 2 emissions and dividing by its turnover.
Global 800 Carbon Rank 800 24 1 Carbon Ranking of 800 international companies. Ranking is determined by EIO Methodology. See Source Info sheet for comments on it
No. of Scope 3 Categories Reported 1 2 15 This column indicates the number of Scope 3 Categories reported. Once placed into one of the four Disclosure Categories, companies are ranked by the number of Scope 3 categories disclosed.
Reported Scope 1+2 Total (tCO2e) 282000000 700000 843 The total reported Scope 1 (all direct emissions) and Scope 2 (indirect electricity emissions) of the company in metric tonnes of CO2 equivalent (tCO2e) as defined by the Greenhouse Gas Protocol
Accepted or Inferred Scope 3 Intensity 8547.13 291.54 64.51 Unless the company reports all 15 Scope 3 categories as defined by the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Standard, an inferred figure based on the highest reported intensity for that sector, across the Global ET Universe, is shown
Category No Public Data Green Public, Complete, and Verified data Companies are placed into one of four data or 'disclosure' categories: 1) Public, Complete, and Verified data; 2) Public, Complete, and Unverified data; 3) Public, Incomplete, Verified or Unverified data; 4) No Public Data
Combined Scope 1+2+3 Intensity 12161.68 166.4 34.24 Combined Scope 1+2_3 Intensity is calculated by adding together a company's Scope 1 and Scope 2 emissions at 100% (disclosed or inferred) + 50% of Scope 3 emissions (disclosed or inferred).
Market Value ($Million) 1667.87 58965 358143.1 A company's market value, or market capitalism (number of shares times x share price). This value was taken on 23.08.2011
SUBSCRIPTION INFO
Description NA Description of the company's product.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
ceo:numberOfRatings 1 45 4026 The number of ratings of the CEO
ceo:pctApprove 0 80 100 Percent of ratings of the CEO that were approving
ceo:title NA The title of the company's CEO
employer:numberOfRatings 1 311 6549 The number of Glassdoor users who have rated this company as a place to work.
Glassdoor Employer Ratings 1 3.3 5 The Top Companies for Work-Life Balance list is based on employee feedback shared in company reviews on Glassdoor.
SUBSCRIPTION INFO
CO2 Productivity 607.9556 47987.1437 5209401.5137 NA
Leadership Diversity 0 0.25 0.5 NA
Rank 100 72 1 NA
SUBSCRIPTION INFO
Size NA Large NA NA
Region NA Europe NA NA
Report Html Address NA http://www.astrazeneca-annualreports.com/2011/ NA NA
Report Pdf Address NA http://www.astrazeneca-annualreports.com/2011/documents/pdfs/annual_report_pdf_entire.pdf NA NA
Report reference IFC Performance Standards? NA No NA NA
Report reference ISO Standards? NA No NA NA
Report Title NA AstraZeneca Annual Report NA NA
Sector NA Healthcare Products NA NA
Sector Supplements (Final) NA Not Applicable NA NA
Application Level Undeclared B+ A+ G3 Application Levels indicate to which extent the GRI Guidelines have been utilized in the reporting and which set and number of disclosures have been addressed in the reporting. There are three Application Levels A, B and C.
Country (HQ) NA United Kingdom NA NA
Date Added To Sr List NA March 27, 2013 NA NA
SUBSCRIPTION INFO
Guidelines NA GRI - G3.1 NA This field indicates which version of the GRI Guidelines is used for the reporting. As of publication year 2009, GRI only includes reporting that makes use of the G3 Guidelines, which were released in October 2006.
Integrated No Yes Yes GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
Publication Year 2013 GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
Region NA Europe NA Region the organization operates in.
Report Html Address NA http://www.astrazeneca.com/Responsibility/Reporting-performance NA URL of the report location.
Report Pdf Address NA http://www.astrazeneca-annualreports.com/2012/documents/eng_download_centre/annual_report.pdf NA Location of a PDF version of the report.
Report Title NA 2012 Annual Report NA Title of the report.
Sector NA Healthcare Products NA Industry sector.
Sector Supplements (Final) NA Not Applicable NA This field indicates if the reporting organization has made use of one of the final Sector Supplements and which one. If ‘not used’ is indicated, it means that one of the final Sector Supplements is applicable, but has not been used. If ‘not applicable’ i
Size NA Large NA GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Envtl. Mgmt. 28.6 75.8 91.9 Based on an analysis of companies tracked in Sustainalytics’ Global Platform, the Environmental Management Score is an assessment of how a company manages its environmental performance through policies, programs, targets, certifications, and the like. To
Green Score 0 71.2 100 NA
Rank 500 69 1 NA
Disclosure 0 82 100 Environmental disclosure was included as a stand-alone score to assess each company’s transparency with regard to its environmental performance. Specifically, this score evaluates the breadth and quality of company environmen
SUBSCRIPTION INFO
Carbon Productivity 0.015 0.51 0.963 GHG Productivity defined as Revenue ($US) / Total Greenhouse gas (GHG) Emissions (CO2e).
Energy Productivity 0.007 0.512 0.957 Energy Productivity defined as Revenue ($US) / Total Energy Consumption (GJ).
Newsweek Green Score 0.0 0.609 0.843 This score is derived from the following component scores: an Energy Productivity,Carbon Productivity, Water Productivity, Waste Productivity, Reputation, Pay Link, Sustainability Themed Committee, Audit ; weighted at 45 percent, 45 percent, and 10 percen
Pay Link No Yes Yes A mechanism to link the remuneration of any member of a company's senior executive team with the achievement of environmental performance targets.
Rank 500 57 1
Reputation 0.005 0.423 1 The Reputation score is made up of two components: (1) The RepRisk Index, which is a quantitative measure that captures criticism and quantifies a company exposure to ESG risks. (2) The second component is based on the number of environmental issues that
Sustainability Themed Committee No Yes Yes The existence of a committee at the Board of Directors level whose mandate is related to the sustainability of the company, including but not limited to environmental matters.
Waste Productivity 0.014 0.486 0.97 Waste Productivity is defined as Revenue ($US) / [Total waste generated (metric tonnes) – waste recycled/reused (metric tonnes)].
Water Productivity 0.012 0.652 0.992 Water Productivity is defined as Revenue ($US) / Total water use (m3).
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Corporate Governance 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
Current RRI 86 11 0 The RepRisk Index (RRI) is a quantitative risk measure that captures criticism and quantifies a company's exposure to controversial environmental, social and governance (ESG) issues. It does not measure a company's overall reputation, but rather is an indicator of their reputational risk.The Current RRI value indicates the current level of criticism about a company.
Employee Relations 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
Environmental FootPrint 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
SUBSCRIPTION INFO
Rank 400 72 1 REPORTWATCH RATING
Report Rating D B+ A REPORTWATCH RATING
SUBSCRIPTION INFO
Value of USG Contracts (in millions) 990 2 1 Value of Iranian contracts.
Withdrawn NA Was the association with Iran withdrawn?
Nationality United Kingdom Country the company is in.
On the list Yes Yes Is the company on the list.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
include_measurement 0 1 1 Does your COP identify targets, define performance indicators and measure outcomes?
references_anti_corruption 0 1 1 Does your COP contain description of actions, and when relevant policies, related to anti-corruption?
references_environment 0 1 1 Does your COP contain description of actions, and when relevant policies, related to the environment?
references_human_rights 0 1 1 Does your COP contain description of actions, and when relevant policies, related to human rights?
references_labour 0 1 1 Does your COP contain description of actions, and when relevant policies, related to labour rights?
starts_on NA 01/01/2012 NA Start Date
differentiation NA advanced NA At what level is the declarer?
ends_on NA 12/01/2012 NA End Date
format NA sustainability_report NA How is your COP shared with stakeholders?
SUBSCRIPTION INFO
ends_on NA 03/01/2014 NA End Date
format NA sustainability_report NA How is your COP shared with stakeholders?
include_continued_support_statement 0 1 1 Does your COP contain a statement by the CEO (or equivalent) expressing continued support for the Global Compact and renewing your company’s ongoing commitment to the initiative and its principles?
include_measurement 0 1 1 Does your COP identify targets, define performance indicators and measure outcomes?
references_anti_corruption 0 1 1 Does your COP contain description of actions, and when relevant policies, related to anti-corruption?
references_environment 0 1 1 Does your COP contain description of actions, and when relevant policies, related to the environment?
references_human_rights 0 1 1 Does your COP contain description of actions, and when relevant policies, related to human rights?
references_labour 0 1 1 Does your COP contain description of actions, and when relevant policies, related to labour rights?
starts_on NA 03/01/2013 NA Start Date
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Weighted score 1.2 2.7 5.9

Flags

(Other Indicators - things that don’t affect ratings but that help identify or classify companies)

SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
You have put report(s) in your cart
Go to my cart
Ok